A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Condition: TNBC - Triple-Negative Breast Cancer Interventions: Drug: Camrelizumab Plus Chemotherapy and Famitinib; Drug: Camrelizumab Plus Chemotherapy Sponsor: Fudan University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Research | Study